Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoHealth (GOCO) Research & Development (2019 - 2025)

Historic Research & Development for GoHealth (GOCO) over the last 7 years, with Q3 2025 value amounting to $17.2 million.

  • GoHealth's Research & Development fell 6224.21% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.8 million, marking a year-over-year decrease of 1112.3%. This contributed to the annual value of $222.4 million for FY2024, which is 629.92% up from last year.
  • Latest data reveals that GoHealth reported Research & Development of $17.2 million as of Q3 2025, which was down 6224.21% from $26.2 million recorded in Q2 2025.
  • GoHealth's Research & Development's 5-year high stood at $123.3 million during Q4 2021, with a 5-year trough of $17.2 million in Q3 2025.
  • Moreover, its 5-year median value for Research & Development was $51.2 million (2022), whereas its average is $58.3 million.
  • In the last 5 years, GoHealth's Research & Development soared by 11809.89% in 2021 and then tumbled by 6224.21% in 2025.
  • Quarter analysis of 5 years shows GoHealth's Research & Development stood at $123.3 million in 2021, then tumbled by 47.49% to $64.8 million in 2022, then rose by 16.13% to $75.2 million in 2023, then grew by 19.26% to $89.7 million in 2024, then tumbled by 80.82% to $17.2 million in 2025.
  • Its Research & Development was $17.2 million in Q3 2025, compared to $26.2 million in Q2 2025 and $51.7 million in Q1 2025.